Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loteprednol versus dexamethasone after cataract surgery
2007-005621-30Phase 4Terminated
- Sponsor
- Bausch + Lomb
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of loteprednol etabonate, dexamethasone and indomethacin in ocular inflammation (2 arms), sponsored by Bausch + Lomb. Primary endpoints: Prevention or reduction of ocular inflammation at Day 7, Adverse events and 4 more. Started Nov 2008; status: terminated.
02
Drugs
loteprednol etabonatedexamethasoneindomethacin
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on 2007-005621-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005621-30.